Teacher Retirement System of Texas Buys 3,086 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Teacher Retirement System of Texas increased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 20.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,825 shares of the company’s stock after acquiring an additional 3,086 shares during the period. Teacher Retirement System of Texas’ holdings in Day One Biopharmaceuticals were worth $226,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its holdings in Day One Biopharmaceuticals by 178.5% in the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock worth $103,254,000 after purchasing an additional 4,750,936 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Day One Biopharmaceuticals during the third quarter valued at approximately $9,607,000. Wellington Management Group LLP lifted its stake in Day One Biopharmaceuticals by 142.1% in the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company’s stock worth $10,052,000 after purchasing an additional 423,543 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Day One Biopharmaceuticals by 18.4% during the third quarter. Janus Henderson Group PLC now owns 2,177,197 shares of the company’s stock valued at $30,307,000 after buying an additional 337,928 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 10.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock valued at $19,961,000 after acquiring an additional 136,458 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Down 4.0 %

DAWN stock opened at $7.61 on Wednesday. Day One Biopharmaceuticals, Inc. has a twelve month low of $7.52 and a twelve month high of $18.07. The firm has a market cap of $771.31 million, a price-to-earnings ratio of -7.39 and a beta of -1.38. The business’s fifty day simple moving average is $10.41 and its two-hundred day simple moving average is $12.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million. Research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This represents a 10.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on DAWN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Wedbush reissued an “outperform” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. cut their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, March 25th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $32.29.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.